India, Sept. 14 -- Bionano Genomics, Inc. (BNGO) announced that three independently authored, peer-reviewed studies have demonstrated that optical genome mapping (OGM) can uncover clinically significant structural genomic alterations across myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and therapy-related myeloid neoplasms- findings often missed by conventional cytogenetic methods such as karyotyping, FISH, and targeted sequencing panels.
MDS and AML are aggressive hematologic malignancies where accurate genomic risk stratification is essential for treatment planning, including decisions around allogeneic transplant and targeted therapies. Conventional cytogenetics frequently fails to detect complex structural variants, es...